PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers (original) (raw)

• Sharma, A. Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine 12, 2137–2148 (2017).
  CAS PubMed Google Scholar
• Garcia-Mayea, Y., Mir, C., Masson, F., Paciucci, R. & LLeonart, M. E. Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin. Cancer Biol. 60, 166–180 (2020).
  CAS PubMed Google Scholar
• Yang, C. et al. Kanglaite reverses multidrug resistance of HCC by inducing apoptosis and cell cycle arrest via PI3K/AKT pathway. OncoTargets Ther. 11, 983–996 (2018).
  Google Scholar
• Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48–58 (2002).
  CAS PubMed Google Scholar
• DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11–20 (2008).
  CAS PubMed Google Scholar
• Zhang, X. et al. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway. Mol. Med. Rep. 15, 1869–1876 (2017).
  CAS PubMed Google Scholar
• Soltani, A., Torki, S., Ghahfarokhi, M. S., Jami, M. S. & Ghatrehsamani, M. Targeting the phosphoinositide 3-kinase/AKT pathways by small molecules and natural compounds as a therapeutic approach for breast cancer cells. Mol. Biol. Rep. 46, 4809–4816 (2019).
  CAS PubMed Google Scholar
• Chen, Y. et al. The critical role of PTEN/PI3K/AKT signaling pathway in shikonin-induced apoptosis and proliferation inhibition of chronic myeloid leukemia. Cell. Physiol. Biochem.l. 47, 981–993 (2018).
  CAS Google Scholar
• Wu, D. M. et al. The PAX6-ZEB2 axis promotes metastasis and cisplatin resistance in non-small cell lung cancer through PI3K/AKT signaling. Cell Death Dis. 10, 349 (2019).
  PubMed PubMed Central Google Scholar
• Ediriweera, M. K., Tennekoon, K. H. & Samarakoon, S. R. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin. Cancer Biol. 59, 147–160 (2019).
  CAS PubMed Google Scholar
• Rahmani, F. et al. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma. J. Cell. Physiol. 235, 4146–4152 (2020).
  CAS PubMed Google Scholar
• Rittler, D. et al. The antitumor effect of lipophilic bisphosphonate BPH1222 in melanoma models: the role of the PI3K/Akt pathway and the small G protein Rheb. Int. J. Mol. Sci. 20, 4917 (2019).
  CAS PubMed Central Google Scholar
• Ellis, H. & Ma, C. X. PI3K inhibitors in breast cancer therapy. Curr. Oncol. Rep. 21, 110 (2019).
  PubMed Google Scholar
• Rubinstein, M. M. et al. Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Cancer 126, 1274–1282 (2020).
  CAS PubMed Google Scholar
• De Marco, C. et al. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. PLoS ONE 8, e55362 (2013).
  PubMed PubMed Central Google Scholar
• Harding, J. J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 25, 2116–2126 (2019).
  CAS PubMed Google Scholar
• Millis, S. Z. et al. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. Cancer 125, 1185–1199 (2019).
  CAS PubMed Google Scholar
• Wang, D. G. et al. Anti-tumor activity of the X-linked inhibitor of apoptosis (XIAP) inhibitor embelin in gastric cancer cells. Mol. Cell. Biochem. 386, 143–152 (2014).
  CAS PubMed Google Scholar
• Jin, J., Xiong, Y. & Cen, B. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer. Anti-cancer Drugs 28, 1141–1149 (2017).
  CAS PubMed PubMed Central Google Scholar
• Rocha Gda, G., Oliveira, R. R., Kaplan, M. A. & Gattass, C. R. 3beta-acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity. Eur. J. Pharmacol. 741, 140–149 (2014).
  PubMed Google Scholar
• Tasioudi, K. E. et al. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma. Acta Pathol. Microbiol. Immunol. Scand. 123, 639–647 (2015).
  CAS Google Scholar
• House, C. D. et al. NFkappaB promotes ovarian tumorigenesis via classical pathways that support proliferative cancer cells and alternative pathways that support ALDH(+) cancer stem-like cells. Cancer Res. 77, 6927–6940 (2017).
  CAS PubMed PubMed Central Google Scholar
• Sui, H. et al. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-kappaB pathway. BMC Complement. Altern. Med. 14, 279 (2014).
  PubMed PubMed Central Google Scholar
• Zhu, D. D. et al. Significance of NF-kappaB activation in immortalization of nasopharyngeal epithelial cells. Int. J. Cancer 138, 1175–1185 (2016).
  CAS PubMed Google Scholar
• Kuznetsov, V. A., Tang, Z. & Ivshina, A. V. Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets. BMC Genom. 18, 692 (2017).
  Google Scholar
• Wu, S. J., Chen, J., Wu, B., Wang, Y. J. & Guo, K. Y. MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma. J. Exp. Clin. Cancer Res. 37, 18 (2018).
  PubMed PubMed Central Google Scholar
• Kyrochristos, I. D., Ziogas, D. E. & Roukos, D. H. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. Med. Res. Rev. 39, 1205–1227 (2019).
  CAS PubMed Google Scholar
• Oh, S., Kim, H., Nam, K. & Shin, I. Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3beta/beta-catenin/survivin signaling pathway in breast cancer cells. Arch. Biochem. Biophys. 636, 110–122 (2017).
  CAS PubMed Google Scholar
• Lampada, A. et al. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. Cell Death Differ. 24, 1045–1062 (2017).
  CAS PubMed PubMed Central Google Scholar
• Tazzari, P. L. et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21, 427–438 (2007).
  Article CAS PubMed Google Scholar
• Zhang, X. et al. Targeting glycometabolic reprogramming to restore the sensitivity of leukemia drug-resistant K562/ADM cells to adriamycin. Life Sci. 215, 1–10 (2018).
  Article PubMed CAS Google Scholar
• Shariati, M. & Meric-Bernstam, F. Targeting AKT for cancer therapy. Expert Opin. Investig. Drugs 28, 977–988 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Yamamoto, T. et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat. Commun. 5, 3480 (2014).
  Article PubMed CAS Google Scholar
• Fischer, B., Frei, C., Moura, U., Stahel, R. & Felley-Bosco, E. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy. Lung Cancer 78, 23–29 (2012).
  Article PubMed Google Scholar
• Liu, B., Wang, C., Chen, P., Cheng, B. & Cheng, Y. RACKI induces chemotherapy resistance in esophageal carcinoma by upregulating the PI3K/AKT pathway and Bcl-2 expression. OncoTargets Ther. 11, 211–220 (2018).
  Article Google Scholar
• Sochalska, M., Tuzlak, S., Egle, A. & Villunger, A. Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J. 282, 834–849 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, Y. H., Wu, Y. L., Tashiro, S., Onodera, S. & Ikejima, T. Reactive oxygen species contribute to oridonin-induced apoptosis and autophagy in human cervical carcinoma HeLa cells. Acta Pharmacol. Sin. 32, 1266–1275 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Goan, Y. G., Wu, W. T., Liu, C. I., Neoh, C. A. & Wu, Y. J. Involvement of mitochondrial dysfunction, endoplasmic reticulum stress, and the PI3K/AKT/mTOR pathway in nobiletin-induced apoptosis of human bladder cancer cells. Molecules. https://doi.org/10.3390/molecules24162881 (2019).
• Volkmann, N., Marassi, F. M., Newmeyer, D. D. & Hanein, D. The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death Differ. 21, 206–215 (2014).
  Article CAS PubMed Google Scholar
• Choi, E. et al. AKT1-targeted proapoptotic activity of compound K in human breast cancer cells. J. Ginseng Res. 43, 692–698 (2019).
  Article PubMed PubMed Central Google Scholar
• Adams, J. M. & Cory, S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 25, 27–36 (2018).
  Article CAS PubMed Google Scholar
• Li, P. et al. Nicotinic agonist inhibits cardiomyocyte apoptosis in CVB3-induced myocarditis via alpha3beta4-nAChR/PI3K/Akt-dependent survivin upregulation. Oxid. Med. Cell. Longev. 2019, 9496419 (2019).
  PubMed PubMed Central Google Scholar
• Heavey, S., O’Byrne, K. J. & Gately, K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat. Rev. 40, 445–456 (2014).
  Article CAS PubMed Google Scholar
• Garcia-Regalado, A., Vargas, M., Garcia-Carranca, A. & Arechaga-Ocampo, E., . & Gonzalez-De la Rosa, C. H.Activation of Akt pathway by transcription-independent mechanisms of retinoic acid promotes survival and invasion in lung cancer cells. Mol. Cancer 12, 44 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Geng, H. X. et al. 14,15-EET suppresses neuronal apoptosis in ischemia-reperfusion through the mitochondrial pathway. Neurochem. Res. 42, 2841–2849 (2017).
  Article CAS PubMed Google Scholar
• Wang, J. H., Nao, J. F., Zhang, M. & He, P. 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol. 35, 11985–11994 (2014).
  Article CAS PubMed Google Scholar
• Fei, B., Chi, A. L. & Weng, Y. Hydroxycamptothecin induces apoptosis and inhibits tumor growth in colon cancer by the downregulation of survivin and XIAP expression. World J. Surg. Oncol. 11, 120 (2013).
  Article PubMed PubMed Central Google Scholar
• Fraser, M. et al. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 63, 7081–7088 (2003).
  CAS PubMed Google Scholar
• Cheng, J. Q. et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updates 5, 131–146 (2002).
  Article CAS Google Scholar
• Kahana, S. et al. Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell. Signal. 23, 1348–1357 (2011).
  Article CAS PubMed Google Scholar
• Kaufmann, T., Strasser, A. & Jost, P. J. Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ. 19, 42–50 (2012).
  Article CAS PubMed Google Scholar
• Balaji, S. et al. NF-kappaB signaling and its relevance to the treatment of mantle cell lymphoma. J. Hematol. Oncol. 11, 83 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Qian, H. et al. X-linked inhibitor of apoptosis protein inhibitor Embelin induces apoptosis via PI3K/Akt pathway and inhibits invasion in osteosarcoma cells. J. Cancer Res. therapeutics 14, S648–S655 (2018).
  Article CAS Google Scholar
• Ali, R. et al. ATM regulated PTEN degradation Is XIAP E3 ubiquitin ligase mediated in p85alpha deficient cancer cells and influence platinum sensitivity. Cells. https://doi.org/10.3390/cells8101271 (2019).
• Asselin, E., Mills, G. B. & Tsang, B. K. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res. 61, 1862–1868 (2001).
  CAS PubMed Google Scholar
• Dan, H. C. et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 291, 22846 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, X., Wu, Z., Mei, Y. & Wu, M. XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling. EMBO J. 32, 2204–2216 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Li, X. et al. Down-regulated lncRNA SLC25A5-AS1 facilitates cell growth and inhibits apoptosis via miR-19a-3p/PTEN/PI3K/AKT signalling pathway in gastric cancer. J. Cell. Mol. Med. 23, 2920–2932 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Xu, S. et al. Metformin suppresses tumor progression by inactivating stromal fibroblasts in ovarian cancer. Mol. Cancer Ther. 17, 1291–1302 (2018).
  Article CAS PubMed Google Scholar
• Ghandadi, M. et al. Wnt-beta-catenin signaling pathway, the Achilles’ heels of cancer multidrug resistance. Curr. Pharm. Des. 25, 4192–4207 (2019).
  Article CAS PubMed Google Scholar
• Zhang, P., Chen, X. B., Ding, B. Q., Liu, H. L. & He, T. Down-regulation of ABCE1 inhibits temozolomide resistance in glioma through the PI3K/Akt/NF-kappaB signaling pathway. Biosci. Rep. https://doi.org/10.1042/BSR20181711 (2018).
• Usman, M. W. et al. Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-kappaB signaling. Cell Death Dis. 9, 809 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Yasuda, T. Hyaluronan inhibits Akt, leading to nuclear factor-kappaB down-regulation in lipopolysaccharide-stimulated U937 macrophages. J. Pharmacol. Sci. 115, 509–515 (2011).
  Article CAS PubMed Google Scholar
• Chen, P. et al. Luteolin inhibits cell proliferation and induces cell apoptosis via down-regulation of mitochondrial membrane potential in esophageal carcinoma cells EC1 and KYSE450. Oncotarget 8, 27471–27480 (2017).
  Article PubMed PubMed Central Google Scholar
• Brown, K. K. & Toker, A. The phosphoinositide 3-kinase pathway and therapy resistance in cancer. F1000prime Rep. 7, 13 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Dutton, A., Reynolds, G. M., Dawson, C. W., Young, L. S. & Murray, P. G. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR. J. Pathol. 205, 498–506 (2005).
  Article CAS PubMed Google Scholar
• Hu, Y. et al. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Cell Death Dis. 6, e2020 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Eberle, J. Countering TRAIL resistance in melanoma. Cancers. https://doi.org/10.3390/cancers11050656 (2019).
• Ni, Z. & Yi, J. Oxymatrine induces nasopharyngeal cancer cell death through inhibition of PI3K/AKT and NFkappaB pathways. Mol. Med. Rep. 16, 9701–9706 (2017).
  Article CAS PubMed Google Scholar
• Chen, W., Liu, X., Yuan, S. & Qiao, T. HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K/Akt/NF-kappaB signaling pathway. Oncol. Lett. 15, 3883–3889 (2018).
  PubMed PubMed Central Google Scholar
• Brotelle, T. & Bay, J. O. PI3K-AKT-mTOR pathway: description, therapeutic development, resistance, predictive/prognostic biomarkers and therapeutic applications for cancer. Bull. Cancer 103, 18–29 (2016).
  PubMed Google Scholar
• Tong, X. & Pelling, J. C. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anti-cancer Agents Med. Chem. 13, 971–978 (2013).
  CAS Google Scholar
• Deng, L. et al. The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia. Acta Pharmacol. Sin. 38, 382–391 (2017).
  CAS PubMed PubMed Central Google Scholar
• Mabuchi, S., Kuroda, H., Takahashi, R. & Sasano, T. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol. Oncol. 137, 173–179 (2015).
  Article CAS PubMed Google Scholar
• Kumar, V. et al. Therapeutic suppression of mTOR (mammalian target of rapamycin) signaling prevents and reverses salt-induced hypertension and kidney injury in dahl salt-sensitive rats. Hypertension 73, 630–639 (2019).
  Article CAS PubMed Google Scholar
• Dai, Y. et al. lncRNA MEG3 suppresses the tumorigenesis of hemangioma by sponging miR-494 and regulating PTEN/ PI3K/AKT pathway. Cell. Physiol. Biochem. 51, 2872–2886 (2018).
  Article CAS PubMed Google Scholar
• Liu, P. et al. PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex. Cancer Discov. 5, 1194–1209 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, G., Murashige, D. S., Humphrey, S. J. & James, D. E. A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation. Cell Rep. 12, 937–943 (2015).
  Article CAS PubMed Google Scholar
• Mercer, P. F. et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax 71, 701–711 (2016).
  Article PubMed Google Scholar
• Yu, X., Zheng, H., Chan, M. T. & Wu, W. K. Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. Am. J. Cancer Res. 7, 1769–1778 (2017).
  CAS PubMed PubMed Central Google Scholar
• Yue, D. & Qin, X. miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells. Cancer Gene Ther. 26, 1–10 (2019).
  CAS PubMed Google Scholar
• Zeng, L. et al. Long non-coding RNA XLOC_006753 promotes the development of multidrug resistance in gastric cancer cells through the PI3K/AKT/mTOR signaling pathway. Cell. Physiol. Biochem. 51, 1221–1236 (2018).
  CAS PubMed Google Scholar
• Li, Z., Qian, J., Li, J. & Zhu, C. Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp. Ther. Med. 18, 435–442 (2019).
  CAS PubMed PubMed Central Google Scholar
• Patel, S., Macaulay, K. & Woodgett, J. R. Tissue-specific analysis of glycogen synthase kinase-3alpha (GSK-3alpha) in glucose metabolism: effect of strain variation. PLoS ONE 6, e15845 (2011).
  CAS PubMed PubMed Central Google Scholar
• Wang, W. et al. NOR1 suppresses cancer stem-like cells properties of tumor cells via the inhibition of the AKT-GSK-3beta-Wnt/beta-catenin-ALDH1A1 signal circuit. J. Cell. Physiol. 232, 2829–2840 (2017).
  CAS PubMed Google Scholar
• von Achenbach, C. et al. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models. J. Neurochem. 153, 510–524 (2020).
  PubMed Google Scholar
• Zhao, Z. A. et al. Adenosine A2A receptor inactivation alleviates early-onset cognitive dysfunction after traumatic brain injury involving an inhibition of tau hyperphosphorylation. Transl. Psychiatry 7, e1123 (2017).
  CAS PubMed PubMed Central Google Scholar
• Zhou, Q. et al. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol. Cancer Ther. 8, 1684–1691 (2009).
  CAS PubMed Google Scholar
• Huber, A. H. & Weis, W. I. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 105, 391–402 (2001).
  CAS PubMed Google Scholar
• Ram Makena, M. et al. Wnt/beta-catenin signaling: the culprit in pancreatic carcinogenesis and therapeutic resistance. Int. J. Mol. Sci. https://doi.org/10.3390/ijms20174242 (2019).
• Wang, G. et al. HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3beta/PTEN/Akt axis. Proc. Natl Acad. Sci. USA 112, 2853–2858 (2015).
  CAS PubMed PubMed Central Google Scholar
• Li, B., Yuan, Z., Jiang, J. & Rao, Y. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway. Biosci. Rep. https://doi.org/10.1042/BSR20181693 (2018).
• Hasanovic, A. & Mus-Veteau, I. Targeting the multidrug transporter Ptch1 potentiates chemotherapy efficiency. Cells. https://doi.org/10.3390/cells7080107 (2018).
• Zhao, R. Q. et al. Y6, an epigallocatechin gallate derivative, reverses ABCG2-mediated mitoxantrone resistance. Front. Pharmacol. 9, 1545 (2018).
  CAS PubMed Google Scholar
• Ranjbar, S. et al. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells. Toxicol. Appl. Pharmacol. 362, 136–149 (2019).
  CAS PubMed Google Scholar
• Guo, Q. et al. Ubenimex reverses MDR in gastric cancer cells by activating caspase-3-mediated apoptosis and suppressing the expression of membrane transport proteins. BioMed. Res. Int. 2019, 4390839 (2019).
  PubMed PubMed Central Google Scholar
• Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152–162 (1976).
  CAS PubMed Google Scholar
• Levy, E. S. et al. Reversible inhibition of efflux transporters by hydrogel microdevices. Eur. J. Pharm. Biopharm. 145, 76–84 (2019).
  CAS PubMed PubMed Central Google Scholar
• Hashimoto, N. et al. Metabolome analysis reveals dermal histamine accumulation in murine dermatitis provoked by genetic deletion of P-glycoprotein and breast cancer resistance protein. Pharm. Res. 36, 158 (2019).
  PubMed Google Scholar
• Teng, Y. N., Wang, Y. H., Wu, T. S., Hung, H. Y. & Hung, C. C. Zhankuic acids A, B and C from Taiwanofungus camphoratus act as cytotoxicity enhancers by regulating P-glycoprotein in multi-drug resistant cancer cells. Biomolecules. https://doi.org/10.3390/biom9120759 (2019).
• Muthusamy, G., Gunaseelan, S. & Prasad, N. R. Ferulic acid reverses P-glycoprotein-mediated multidrug resistance via inhibition of PI3K/Akt/NF-kappaB signaling pathway. J. Nutr. Biochem. 63, 62–71 (2019).
  CAS PubMed Google Scholar
• Xie, X., Tang, B., Zhou, J., Gao, Q. & Zhang, P. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol. Rep. 30, 773–782 (2013).
  CAS PubMed Google Scholar
• Kaewpiboon, C. et al. Feroniellin A-induced autophagy causes apoptosis in multidrug-resistant human A549 lung cancer cells. Int. J. Oncol. 44, 1233–1242 (2014).
  CAS PubMed Google Scholar
• Yuan, Z. et al. Targeting CD133 reverses drug-resistance via the AKT/NF-kappaB/MDR1 pathway in colorectal cancer. Br. J. Cancer 122, 1342–1353 (2020).
  CAS PubMed PubMed Central Google Scholar
• Shahbazi, R. et al. Hesperidin inhibits insulin-induced phosphoinositide 3-kinase/Akt activation in human pre-B cell line NALM-6. J. Cancer Res. Ther. 14, 503–508 (2018).
  CAS PubMed Google Scholar
• Cai, H., Li, L., Jiang, J., Zhao, C. & Yang, C. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway. Phytother. Res. 33, 1683–1688 (2019).
  CAS PubMed Google Scholar
• Li, Y. et al. Guajadial reverses multidrug resistance by inhibiting ABC transporter expression and suppressing the PI3K/Akt pathway in drug-resistant breast cancer cells. Chem.-Biol. Interact. 305, 98–104 (2019).
  CAS PubMed Google Scholar
• Roundhill, E. A. & Burchill, S. A. Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria. Br. J. Cancer 106, 1224–1233 (2012).
  CAS PubMed PubMed Central Google Scholar
• Tripathi, S. C. et al. MCAM mediates chemoresistance in small-cell lung cancer via the PI3K/AKT/SOX2 signaling pathway. Cancer Res. 77, 4414–4425 (2017).
  CAS PubMed PubMed Central Google Scholar
• Li, S. et al. The roles of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRPs/ABCCs) in the excretion of cycloicaritin-3-O-glucoronide in UGT1A1-overexpressing HeLa cells. Chem.-Biol. Interact. 296, 45–56 (2018).
  CAS PubMed PubMed Central Google Scholar
• Abdul-Ghani, R. et al. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25, 1743–1752 (2006).
  CAS PubMed Google Scholar
• Yao, J., Wei, X. & Lu, Y. Chaetominine reduces MRP1-mediated drug resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells. Biochem. Biophys. Res. Commun. 473, 867–873 (2016).
  CAS PubMed Google Scholar
• Gao, H. L., Xia, Y. Z., Zhang, Y. L., Yang, L. & Kong, L. Y. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines. Phytomedicine 58, 152885 (2019).
  Article CAS PubMed Google Scholar
• Li, Y. et al. Involvement of the PI3K/Akt/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60/ADR cells. Nutr. Cancer 71, 1007–1018 (2019).
  CAS PubMed Google Scholar
• To, K. K. & Tomlinson, B. Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARgamma agonists. Br. J. Pharmacol. 170, 1137–1151 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Li, H. et al. Comparison of LC–MS/MS-based targeted proteomics and conventional analytical methods for monitoring breast cancer resistance protein expression. Life Sci. 231, 116548 (2019).
  Article CAS PubMed Google Scholar
• Feng, S. et al. Proton pump inhibitor pantoprazole inhibits the proliferation, selfrenewal and chemoresistance of gastric cancer stem cells via the EMT/betacatenin pathways. Oncol. Rep. 36, 3207–3214 (2016).
  CAS PubMed Google Scholar
• Chen, Z. et al. Suppression of ABCG2 inhibits cancer cell proliferation. Int. J. Cancer 126, 841–851 (2010).
  CAS PubMed Google Scholar
• Lin, J. et al. Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway. Oncol. Rep. 38, 2293–2300 (2017).
  CAS PubMed Google Scholar
• Shafran, A. et al. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res. 65, 8414–8422 (2005).
  CAS PubMed Google Scholar
• Wang, L., Lin, N. & Li, Y. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma. Oncol. Rep. 41, 1678–1690 (2019).
  CAS PubMed PubMed Central Google Scholar
• Yeh, Y. C. et al. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma. Modern Pathol. 33, 391–403 (2020).
  CAS Google Scholar
• Lopes-Rodrigues, V. et al. Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles. Sci. Rep. 7, 44541 (2017).
  CAS PubMed PubMed Central Google Scholar
• Robey, R. B. & Hay, N. Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19, 25–31 (2009).
  CAS PubMed Google Scholar
• Ayuk, S. M. & Abrahamse, H. mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro. Cells. https://doi.org/10.3390/cells8050431 (2019).
• Hosios, A. M. et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev. Cell 36, 540–549 (2016).
  CAS PubMed PubMed Central Google Scholar
• Knoechel, B. & Aster, J. C. Metabolic mechanisms of drug resistance in leukemia. Cell Metab. 22, 759–760 (2015).
  CAS PubMed Google Scholar
• Zhu, W. et al. Dihydroartemisinin suppresses glycolysis of LNCaP cells by inhibiting PI3K/AKT pathway and downregulating HIF-1alpha expression. Life Sci. 233, 116730 (2019).
  CAS PubMed Google Scholar
• Ersahin, T., Tuncbag, N. & Cetin-Atalay, R. The PI3K/AKT/mTOR interactive pathway. Mol. Biosyst. 11, 1946–1954 (2015).
  CAS PubMed Google Scholar
• Feng, C. et al. SHBG expression is correlated with PI3K/AKT pathway activity in a cellular model of human insulin resistance. Gynecol. Endocrinol. 34, 567–573 (2018).
  CAS PubMed Google Scholar
• Lee, J. H. et al. EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation. Mol. Cell 70, 197–210. e197 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Pollen, A. A. et al. Establishing cerebral organoids as models of human-specific brain evolution. Cell 176, 743–756. e717 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Marzagalli, M. et al. Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications. Semin. Cancer Biol. 59, 221–235 (2019).
  Article CAS PubMed Google Scholar
• Liu, L. et al. Transgelin 2 promotes paclitaxel resistance, migration, and invasion of breast cancer by directly interacting with PTEN and activating PI3K/Akt/GSK-3beta pathway. Mol. Cancer Ther. 18, 2457–2468 (2019).
  Article CAS PubMed Google Scholar
• Bukowski, K., Kciuk, M. & Kontek, R. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. https://doi.org/10.3390/ijms21093233 (2020).
• Meng, Y. et al. Ursolic acid induces apoptosis of prostate cancer cells via the PI3K/Akt/mTOR pathway. Am. J. Chin. Med. 43, 1471–1486 (2015).
  Article CAS PubMed Google Scholar
• Dong, C. et al. Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway. Am. J. Cancer Res. 10, 263–274 (2020).
  CAS PubMed PubMed Central Google Scholar
• Annageldiyev, C. et al. The PI3K/AKT pathway inhibitor ISC-4 induces apoptosis and inhibits growth of leukemia in preclinical models of acute myeloid leukemia. Front. Oncol. 10, 393 (2020).
  Article PubMed PubMed Central Google Scholar